lidoflazine has been researched along with Cardiomyopathies in 1 studies
Lidoflazine: Coronary vasodilator with some antiarrhythmic action.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kates, RA | 1 |
| Dorsey, LM | 1 |
| Kaplan, JA | 1 |
| Hatcher, CR | 1 |
| Guyton, RA | 1 |
1 other study available for lidoflazine and Cardiomyopathies
| Article | Year |
|---|---|
Pretreatment with lidoflazine, a calcium-channel blocker. Useful adjunct to heterogeneous cold potassium cardioplegia.
Topics: Animals; Aorta; Calcium Channel Blockers; Calcium Chloride; Cardiomyopathies; Cardiopulmonary Bypass | 1983 |